Bangalore, India – Kemwell Biopharma, a global contract development and manufacturing services provider, announced that it has appointed Siddharth J Advant, Ph.D. as President of its Biopharmaceutical Services.
Anurag Bagaria, Chairman and Managing Director, said “Dr. Advant exemplifies Kemwell’s commitment to delivering high performance to its customers. He is a proven leader with over 20 years of experience in the biopharmaceutical industry. His extensive experience in CMC development and commercialization will help Kemwell grow its contract biotech business. As a member of Kemwell’s core committee for strategic growth, Dr. Advant will lead a team of professionals charged with developing and delivering high-quality services in the most efficient manner possible to biopharmaceutical companies globally.
In his 20-year career, Dr. Advant has held a wide variety of leadership positions across the biopharmaceutical industry. He is joining Kemwell from ImClone Systems (a wholly owned subsidiary of Eli Lilly & Co.) where he was Associate VP, CMC Project Management. Prior to ImClone, Dr. Advant was the head of Tunnell Consulting’s West Coast Office. Prior to joining Tunnell, Siddharth Advant, Ph.D. was a Director for Diosynth Biotechnology, heading three primary areas: Project Management & Business Alliances, Technology Transfer & Clinical Operations, and Pharmaceutical Sciences & Stability. In these positions, Dr. Advant was responsible for technical and financial execution of customer projects,development and implementation of technology transfer programs, as well as building and managing an analytical, formulation and cGMP testing laboratory. He worked as a scientist in the pharmaceutical development division at Protein Design Labs, Inc. and as a Program Manager for BioReliance, Inc. where he supervised a cGMP/GLP compliant formulation development business.
Dr. Advant earned a B.S. degree in pharmacy from the University of Poona, India and a Ph.D. in Pharmaceutics from the University of Connecticut School of Pharmacy. He is a Founding Member of the CMC Strategy Forum Advisory Committee, which consists of FDA and Industry members, and served as Chair for the 2008 WCBP Meeting, 2004 AAPS National Biotechnology Conference in Boston and the 2002 AAPS Biotechnology Section. The author of various peer-reviewed articles, Dr. Advant has also made a number of scientific presentations at major industry conferences.
Kemwell provides customized product development and manufacturing solutions to pharmaceutical and biopharmaceutical organizations worldwide. As a 100% contract services provider, Kemwell services over 100 global bio/pharmaceutical companies, including seven of the top 10 Big Pharma. Founded in 1980, Kemwell employs 1200 people, has 10 facilities worldwide and supplies to 80 countries globally.
Read more about Kemwell on www.kemwellbiopharma.com